BR112012018943A8 - medicamento e método para o tratamento e/ou prevenção de um câncer - Google Patents

medicamento e método para o tratamento e/ou prevenção de um câncer

Info

Publication number
BR112012018943A8
BR112012018943A8 BR112012018943A BR112012018943A BR112012018943A8 BR 112012018943 A8 BR112012018943 A8 BR 112012018943A8 BR 112012018943 A BR112012018943 A BR 112012018943A BR 112012018943 A BR112012018943 A BR 112012018943A BR 112012018943 A8 BR112012018943 A8 BR 112012018943A8
Authority
BR
Brazil
Prior art keywords
medicine
treating
preventing cancer
cancer
preventing
Prior art date
Application number
BR112012018943A
Other languages
English (en)
Inventor
Okano Fumiyoshi
Ido Takayoshi
Narita Yoshinori
Original Assignee
Toray Industries
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Toray Industries filed Critical Toray Industries
Publication of BR112012018943A8 publication Critical patent/BR112012018943A8/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/475Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/66Phosphorus compounds
    • A61K31/675Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
BR112012018943A 2010-02-04 2011-02-04 medicamento e método para o tratamento e/ou prevenção de um câncer BR112012018943A8 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2010023455 2010-02-04
PCT/JP2011/052414 WO2011096535A1 (ja) 2010-02-04 2011-02-04 癌の治療及び/又は予防のための医薬品

Publications (1)

Publication Number Publication Date
BR112012018943A8 true BR112012018943A8 (pt) 2017-12-19

Family

ID=44355529

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112012018943A BR112012018943A8 (pt) 2010-02-04 2011-02-04 medicamento e método para o tratamento e/ou prevenção de um câncer

Country Status (16)

Country Link
US (1) US9180187B2 (pt)
EP (1) EP2532367B1 (pt)
JP (1) JP5923984B2 (pt)
KR (1) KR101843807B1 (pt)
CN (2) CN109925511B (pt)
AU (1) AU2011211700B2 (pt)
BR (1) BR112012018943A8 (pt)
CA (1) CA2788720C (pt)
DK (1) DK2532367T3 (pt)
ES (1) ES2691738T3 (pt)
HU (1) HUE040012T2 (pt)
MX (1) MX2012008991A (pt)
PL (1) PL2532367T3 (pt)
PT (1) PT2532367T (pt)
RU (1) RU2624029C2 (pt)
WO (1) WO2011096535A1 (pt)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101638490B1 (ko) 2008-08-05 2016-07-11 도레이 카부시키가이샤 암의 치료 및 예방용 의약 조성물
PT2325648E (pt) 2008-08-05 2014-06-24 Toray Industries Método para detetar cancro
HUE030742T2 (en) 2010-02-04 2017-06-28 Toray Industries A pharmaceutical composition for the treatment and / or prevention of cancer
US8911740B2 (en) 2010-02-04 2014-12-16 Toray Industries, Inc. Pharmaceutical composition for treating and/or preventing cancer
PT2532743E (pt) 2010-02-04 2015-08-04 Toray Industries Composição farmacêutica para o tratamento e/ou a prevenção de cancro
RU2567657C2 (ru) 2010-02-04 2015-11-10 Торэй Индастриз, Инк. Фармацевтическая композиция для лечения и/или профилактики рака
PL2532365T3 (pl) 2010-02-04 2016-12-30 Kompozycja farmaceutyczna do leczenia i/lub zapobiegania nowotworowi
HUE040012T2 (hu) 2010-02-04 2019-02-28 Toray Industries Gyógyászati ágens rák kezelésére és/vagy megelõzésére
RU2610428C2 (ru) 2011-08-04 2017-02-10 Торэй Индастриз, Инк. Фармацевтическая композиция для лечения и/или профилактики злокачественной опухоли
BR112014002621B1 (pt) 2011-08-04 2022-09-20 Toray Industries, Inc Anticorpo, ou seu fragmento, composição farmacêutica, uso de um anticorpo e uso de uma composição farmacêutica
EP2740798B1 (en) * 2011-08-04 2016-12-07 Toray Industries, Inc. Cancer treatment and/or prevention drug composition
KR101980554B1 (ko) 2011-08-04 2019-05-21 도레이 카부시키가이샤 암의 치료 및/또는 예방용 의약 조성물
MX349907B (es) 2011-08-04 2017-08-18 Toray Industries Metodo para detectar cancer pancreatico.
CN103717740B (zh) 2011-08-04 2015-10-21 东丽株式会社 癌的治疗和/或预防用药物组合物
AU2012290949B2 (en) 2011-08-04 2017-03-02 Toray Industries, Inc. Pharmaceutical composition for treatment and/or prevention of pancreatic cancer
ES2749672T3 (es) * 2012-02-21 2020-03-23 Toray Industries Composición farmacéutica para tratar y/o prevenir el cáncer
PL2818483T3 (pl) * 2012-02-21 2018-01-31 Toray Industries Kompozycja lecznicza do leczenia i/lub zapobiegania nowotworowi
HUE044611T2 (hu) 2012-02-21 2019-11-28 Toray Industries Gyógyászati készítmény rák kezelésére
PL2824114T3 (pl) 2012-02-21 2019-11-29 Toray Industries Kompozycja farmaceutyczna do leczenia nowotworu
PL2832366T3 (pl) 2012-03-30 2018-04-30 Toray Industries, Inc. Kompozycja farmaceutyczna do leczenia i/lub zapobiegania rakowi pęcherzyka żółciowego
JP6107654B2 (ja) * 2012-03-30 2017-04-05 東レ株式会社 肝臓癌の治療及び/又は予防用医薬組成物
KR102056137B1 (ko) 2012-07-19 2019-12-16 도레이 카부시키가이샤 암의 검출 방법
PT2876446T (pt) 2012-07-19 2019-03-25 Toray Industries Método para deteção de cancro
JP6447130B2 (ja) 2013-08-09 2019-01-09 東レ株式会社 癌の治療及び/又は予防用医薬組成物
KR20190075921A (ko) 2016-10-28 2019-07-01 도레이 카부시키가이샤 암의 치료 및/또는 예방용 의약 조성물
JP7342701B2 (ja) * 2018-03-30 2023-09-12 東レ株式会社 癌の治療及び/又は予防用医薬組成物
BR112022018157A2 (pt) 2020-03-12 2022-10-25 Toray Industries Medicamento para o tratamento e/ou prevenção do câncer, agentes que aumentam a eficácia de um fármaco e método para o tratamento e/ou prevenção do câncer
JPWO2021182570A1 (pt) 2020-03-12 2021-09-16
JPWO2021182574A1 (pt) 2020-03-12 2021-09-16
US20230140155A1 (en) 2020-03-12 2023-05-04 Toray Industries, Inc. Medicament for treatment and/or prevention of cancer
CA3175127A1 (en) 2020-03-12 2021-09-16 Toray Industries, Inc. Medicament for treatment and/or prevention of cancer
JPWO2022270523A1 (pt) 2021-06-23 2022-12-29
WO2022270524A1 (ja) 2021-06-23 2022-12-29 東レ株式会社 癌の治療及び/又は予防のための医薬品
AU2022319362A1 (en) 2021-07-27 2024-02-29 Toray Industries, Inc. Medicament for treatment and/or prevention of cancer
CN117677398A (zh) 2021-07-27 2024-03-08 东丽株式会社 用于癌的治疗和/或预防的药品
WO2023008461A1 (ja) 2021-07-27 2023-02-02 東レ株式会社 癌の治療及び/又は予防のための医薬品
KR20240051956A (ko) 2021-09-03 2024-04-22 도레이 카부시키가이샤 암의 치료 및/또는 예방용 의약 조성물
WO2024048542A1 (ja) * 2022-08-30 2024-03-07 東レ株式会社 癌の治療及び/又は予防のための医薬品
WO2024048541A1 (ja) * 2022-08-30 2024-03-07 東レ株式会社 癌の治療及び/又は予防のための医薬品

Family Cites Families (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR9508959A (pt) * 1994-09-19 1997-12-30 Ricardo J Moro "Detecção e tratamento de cancer"
US5698396A (en) 1995-06-07 1997-12-16 Ludwig Institute For Cancer Research Method for identifying auto-immunoreactive substances from a subject
US20030118599A1 (en) 1999-04-02 2003-06-26 Corixa Corporation Compositions and methods for the therapy and diagnosis of lung cancer
TW200532020A (en) 1998-07-14 2005-10-01 Corixa Corp Compositions and methods for therapy and diagnosis of prostate cancer
RU2234942C2 (ru) 1998-07-14 2004-08-27 Корикса Корпорейшн Выделенный опухолевый полипептид предстательной железы и кодирующий его полинуклеотид
US6969518B2 (en) 1998-12-28 2005-11-29 Corixa Corporation Compositions and methods for the therapy and diagnosis of breast cancer
WO2000052204A2 (en) 1999-02-22 2000-09-08 Orntoft Torben F Gene expression in bladder tumors
EP1187915A2 (en) * 1999-04-02 2002-03-20 Corixa Corporation Compounds for therapy and diagnosis of lung cancer and methods for their use
US6444425B1 (en) 1999-04-02 2002-09-03 Corixa Corporation Compounds for therapy and diagnosis of lung cancer and methods for their use
US6949245B1 (en) 1999-06-25 2005-09-27 Genentech, Inc. Humanized anti-ErbB2 antibodies and treatment with anti-ErbB2 antibodies
EP1224285A4 (en) 1999-10-29 2004-12-08 Human Genome Sciences Inc 27 HUMAN SECRETED PROTEINS
US20020006404A1 (en) 1999-11-08 2002-01-17 Idec Pharmaceuticals Corporation Treatment of cell malignancies using combination of B cell depleting antibody and immune modulating antibody related applications
AU2001261007A1 (en) 2000-03-29 2001-10-08 Corixa Corporation Compositions and methods for the therapy and diagnosis of lung cancer
US7919467B2 (en) * 2000-12-04 2011-04-05 Immunotope, Inc. Cytotoxic T-lymphocyte-inducing immunogens for prevention, treatment, and diagnosis of cancer
US7408041B2 (en) * 2000-12-08 2008-08-05 Alexion Pharmaceuticals, Inc. Polypeptides and antibodies derived from chronic lymphocytic leukemia cells and uses thereof
US20040029114A1 (en) 2001-01-24 2004-02-12 Eos Technology, Inc. Methods of diagnosis of breast cancer, compositions and methods of screening for modulators of breast cancer
RU2306952C2 (ru) 2001-01-31 2007-09-27 Байоджен Айдек Инк. Лечение в-клеточных злокачественных опухолей с использованием комбинации применений, связанных с антителами, уменьшающими количество b-клеток, и с иммуномодулирующими антителами
AU2002311787A1 (en) 2001-03-28 2002-10-15 Zycos Inc. Translational profiling
WO2002083070A2 (en) * 2001-04-10 2002-10-24 Corixa Corporation Compounds for immunotherapy and diagnosis of colon cancer and methods for their use
WO2002092001A2 (en) 2001-05-11 2002-11-21 Corixa Corporation Compositions and methods for the therapy and diagnosis of lung cancer
US20030190640A1 (en) 2001-05-31 2003-10-09 Mary Faris Genes expressed in prostate cancer
US20040142325A1 (en) 2001-09-14 2004-07-22 Liat Mintz Methods and systems for annotating biomolecular sequences
EP1575480A4 (en) 2002-02-22 2008-08-06 Genentech Inc COMPOSITIONS AND METHODS FOR TREATING DISEASES RELATED TO THE IMMUNE SYSTEM
US20050003390A1 (en) * 2002-05-17 2005-01-06 Axenovich Sergey A. Targets for controlling cellular growth and for diagnostic methods
US20040126379A1 (en) * 2002-08-21 2004-07-01 Boehringer Ingelheim International Gmbh Compositions and methods for treating cancer using cytotoxic CD44 antibody immunoconjugates and chemotherapeutic agents
US20060121029A1 (en) 2002-08-30 2006-06-08 Hiroshi Shiku Method and composition for regulating the activity of regulatory t cells
CA2504144A1 (en) 2002-11-26 2004-06-10 Genentech, Inc. Compositions and methods for the diagnosis of immune related diseases using pro7
WO2004076682A2 (en) 2003-02-26 2004-09-10 Surromed, Inc. Targets for controlling cellular growth and for diagnostic methods
WO2004097051A2 (en) 2003-04-29 2004-11-11 Wyeth Methods for diagnosing aml and mds differential gene expression
KR20060031809A (ko) 2003-06-09 2006-04-13 더 리젠츠 오브 더 유니버시티 오브 미시간 암 치료 및 진단용 조성물 및 방법
US20070048738A1 (en) 2003-07-14 2007-03-01 Mayo Foundation For Medical Education And Research Methods and compositions for diagnosis, staging and prognosis of prostate cancer
US20050032113A1 (en) 2003-07-17 2005-02-10 Mitsubishi Pharma Corporation Membrane protein library for proteome analysis and method for preparing same
EP1711525A2 (en) 2004-01-26 2006-10-18 Debiovision Inc. Neoplasm-specific polypeptides and their uses
CA2560305C (en) 2004-03-19 2016-07-05 Imclone Systems Incorporated Human anti-epidermal growth factor receptor antibody
WO2005100998A2 (en) * 2004-04-16 2005-10-27 Europroteome Ag Membrane markers for use in cancer diagnosis and therapy
DE102004026135A1 (de) 2004-05-25 2006-01-05 Immatics Biotechnologies Gmbh An MHC-Moleküle bindende Tumor-assoziierte Peptide
WO2006002378A2 (en) 2004-06-23 2006-01-05 Avalon Pharmaceuticals Determining cancer-linked genes and therapeutic targets using molecular cytogenetic methods
EP3698807A1 (en) 2005-01-21 2020-08-26 Genentech, Inc. Fixed dosing of her antibodies
US7858324B2 (en) 2005-02-18 2010-12-28 Children's Medical Center Corporation Cyr61 as a biomarker for diagnosis and prognosis of cancers of epithelial origin
KR101310000B1 (ko) 2005-03-11 2013-09-25 싸이퍼젠 바이오시스템즈, 인코포레이티드 난소암 및 자궁내막암에 대한 바이오마커 : 헵시딘
JP2006316040A (ja) 2005-05-13 2006-11-24 Genentech Inc Herceptin(登録商標)補助療法
US8014957B2 (en) 2005-12-15 2011-09-06 Fred Hutchinson Cancer Research Center Genes associated with progression and response in chronic myeloid leukemia and uses thereof
US8211634B2 (en) 2006-02-14 2012-07-03 Dana-Farber Cancer Institute, Inc. Compositions, kits, and methods for identification, assessment, prevention, and therapy of cancer
US20100015724A1 (en) 2006-08-17 2010-01-21 Peter Hornbeck Lysine acetylation sites
US20080107668A1 (en) 2006-08-30 2008-05-08 Immunotope, Inc. Cytotoxic t-lymphocyte-inducing immunogens for prevention, treatment, and diagnosis of cancer
WO2008031041A2 (en) 2006-09-07 2008-03-13 H. Lee Moffitt Cancer Center And Research Institute, Inc. Melanoma gene signature
WO2008059252A2 (en) 2006-11-15 2008-05-22 Oxford Biomedica (Uk) Limited Methods and composition fro t cell receptors which recognize 5t4 antigen
JP5663834B2 (ja) 2008-03-14 2015-02-04 東ソー株式会社 遺伝子組換え抗体の製造方法
PT2325648E (pt) 2008-08-05 2014-06-24 Toray Industries Método para detetar cancro
KR101638490B1 (ko) * 2008-08-05 2016-07-11 도레이 카부시키가이샤 암의 치료 및 예방용 의약 조성물
BRPI0912462B1 (pt) 2008-08-05 2022-03-22 Toray Industries, Inc Uso de um agente indutor de imunidade, uso de um polipeptídeo e uso de um vetor recombinante
BR112012003686B1 (pt) 2009-08-19 2021-09-21 Merck Patent Gmbh Anticorpos monoclonais, seu uso para detecção de complexos de integrina em material ffpe, e polinucleotídeo
EP2480671B8 (en) 2009-09-22 2015-10-28 ProBioGen AG Process for producing molecules containing specialized glycan structures
PL2532365T3 (pl) 2010-02-04 2016-12-30 Kompozycja farmaceutyczna do leczenia i/lub zapobiegania nowotworowi
HUE040012T2 (hu) 2010-02-04 2019-02-28 Toray Industries Gyógyászati ágens rák kezelésére és/vagy megelõzésére
PT2532743E (pt) * 2010-02-04 2015-08-04 Toray Industries Composição farmacêutica para o tratamento e/ou a prevenção de cancro
RU2567657C2 (ru) * 2010-02-04 2015-11-10 Торэй Индастриз, Инк. Фармацевтическая композиция для лечения и/или профилактики рака
HUE030742T2 (en) 2010-02-04 2017-06-28 Toray Industries A pharmaceutical composition for the treatment and / or prevention of cancer
US8911740B2 (en) 2010-02-04 2014-12-16 Toray Industries, Inc. Pharmaceutical composition for treating and/or preventing cancer
MX349907B (es) 2011-08-04 2017-08-18 Toray Industries Metodo para detectar cancer pancreatico.
AU2012290949B2 (en) 2011-08-04 2017-03-02 Toray Industries, Inc. Pharmaceutical composition for treatment and/or prevention of pancreatic cancer
CN103717740B (zh) 2011-08-04 2015-10-21 东丽株式会社 癌的治疗和/或预防用药物组合物
JP6107654B2 (ja) 2012-03-30 2017-04-05 東レ株式会社 肝臓癌の治療及び/又は予防用医薬組成物
PL2832366T3 (pl) 2012-03-30 2018-04-30 Toray Industries, Inc. Kompozycja farmaceutyczna do leczenia i/lub zapobiegania rakowi pęcherzyka żółciowego

Also Published As

Publication number Publication date
JPWO2011096535A1 (ja) 2013-06-13
EP2532367B1 (en) 2018-08-29
DK2532367T3 (en) 2018-11-19
US20120294860A1 (en) 2012-11-22
AU2011211700B2 (en) 2015-06-11
WO2011096535A1 (ja) 2011-08-11
RU2012137503A (ru) 2014-03-10
CN109925511A (zh) 2019-06-25
CA2788720A1 (en) 2011-08-11
MX2012008991A (es) 2012-09-07
CN109925511B (zh) 2024-03-19
PL2532367T3 (pl) 2019-02-28
RU2624029C2 (ru) 2017-06-30
KR20120139720A (ko) 2012-12-27
JP5923984B2 (ja) 2016-05-25
HUE040012T2 (hu) 2019-02-28
US9180187B2 (en) 2015-11-10
PT2532367T (pt) 2018-11-09
ES2691738T3 (es) 2018-11-28
CN102844048A (zh) 2012-12-26
EP2532367A4 (en) 2014-05-28
CA2788720C (en) 2019-08-20
KR101843807B1 (ko) 2018-03-30
EP2532367A1 (en) 2012-12-12
AU2011211700A1 (en) 2012-08-23

Similar Documents

Publication Publication Date Title
BR112012018943A8 (pt) medicamento e método para o tratamento e/ou prevenção de um câncer
BR112012018947A8 (pt) composição farmacêutica para o tratamento e/ou prevenção de um câncer, anticorpo, combinação farmacêutica e método para o tratamento e/ou prevenção de um câncer
BR112012018951A2 (pt) composição farmacêutica, combinação farmacêutica e método para o tratamento e\ou prevenção de um câncer e anticorpo
HUE047006T2 (hu) Anti-caprin-1 antitesteket tartalmazó gyógyászati kompozíció rák kezelésére és/vagy megelõzésére
EP2532364A4 (en) PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OR PREVENTION OF CANCER
EP2818483A4 (en) MEDICINAL COMPOSITION FOR THE TREATMENT AND / OR PREVENTION OF CANCER
BR112014002619A2 (pt) composição farmacêutica e método de tratamento e/ou prevenção de câncer pancreático e combinação farmacêutica
BR112014032105A2 (pt) método para o tratamento de câncer
PL2532680T3 (pl) Kompozycja medyczna do leczenia raka i/lub zapobiegania
PL2740793T3 (pl) Kompozycja leku do leczenia i/lub zapobiegania nowotworowi
BR112015007866A2 (pt) combinação de opióides e fármacos anticancerígenos para o tratamento do câncer.
BR112013011874A2 (pt) compostos e métodos para tratar dor
BR112014004937A2 (pt) método para tratar e/ou prevenir um câncer dependente de ligante de ahr natural e inibidor de ahr
BR112014032053A2 (pt) composto, composição farmacêutica, utilização de um composto, método para o tratamento de câncer e invenção
IL253441A0 (en) A medicine for the prevention and/or treatment of polycystic kidney disease
HK1207557A1 (en) Method and system for treating biological tissue
BRPI1007972A2 (pt) composições de combinação e métodos para o tratamento de câncer
BRPI1008564A2 (pt) métodos e composições para o dignóstico e tratamento de câncer
SMT201700056B (it) Fosfaplatine e relativo utilizzo per il trattamento di cancro
BR112014031512A2 (pt) composição cosmética e método para o tratamento cosmético.
BR112015008798A2 (pt) método para o tratamento de plantas e uso
BR112014031785A2 (pt) composto, composição farmacêutica, utilização do composto, método para o tratamento do câncer e invenção
BR112013028890A2 (pt) composições e métodos para o tratamento de câncer
BR112014032290A2 (pt) composições e métodos para tratar ou prevenir infecção de pneumovírus e doenças associadas.
BR112015003201A2 (pt) composto, composição farmacêutica, uso de um composto e método para tratar ou melhorar o cãncer

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06T Formal requirements before examination [chapter 6.20 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B12B Appeal against refusal [chapter 12.2 patent gazette]